Women’s Health Testing During Perimenopause and Menopause
What to Test, Why It Matters, and How to Track Change Over Time
Women’s health testing during perimenopause and menopause requires a broader and more thoughtful approach than a single annual blood test. Hormones fluctuate daily, symptoms evolve over years, and many early biological changes are not captured by traditional screening alone. For women in their 30s, 40s, and beyond, understanding health trends over time is far more informative than any single lab value.¹–³
Educational disclaimer: This article is for educational purposes only. It is based on peer-reviewed scientific literature, professional society guidelines, and expert consensus. It does not provide medical advice. Women should always discuss symptoms, testing, and care decisions with qualified healthcare professionals.
When Personal and Family History Should Guide Deeper Testing
Importantly, women with a personal or family history of certain medical conditions may benefit from earlier or more comprehensive testing.
These include:
-
Heart disease or stroke¹
-
Type 2 diabetes or metabolic disease⁴
-
Alzheimer’s disease or other dementias⁵
-
Breast, ovarian, colorectal, or hormone-sensitive cancers⁶
-
Autoimmune or chronic inflammatory conditions¹
As a result, it is appropriate for these women to discuss with their healthcare provider whether additional biomarkers, imaging, or genetic testing may be warranted. Risk is cumulative and individualized, shaped by biology, hormones, environment, and family history combined.
Why One Blood Test Is Not the Full Story
During perimenopause, estrogen and progesterone fluctuate unpredictably — sometimes daily. Consequently, a “normal” hormone level on a single test may not reflect how a woman feels or functions over time.
Professional societies emphasize that perimenopause is diagnosed clinically, based on symptoms and menstrual pattern changes, not hormone levels alone.¹–³ Hormone tests provide context, but symptoms provide essential insight.
For this reason, experts increasingly recommend combining:
-
Symptom tracking over time
-
Longitudinal lab trends
-
Metabolic, inflammatory, and cardiometabolic markers
Together, these provide a far more accurate picture of women’s health during midlife.
Cardiometabolic Health: Why Midlife Testing Matters
Cardiovascular disease is the leading cause of death in women, responsible for approximately one in three female deaths worldwide, exceeding all cancers combined.¹,⁷ Importantly, heart disease is a midlife disease that often presents clinically — as heart attack or stroke — in a woman’s 60s, after decades of silent progression.¹,⁷
Large longitudinal cohort studies demonstrate that:
-
Atherosclerosis and metabolic dysfunction begin years earlier
-
Menopause accelerates cardiometabolic risk
-
Declining estrogen contributes to inflammation, insulin resistance, and adverse lipid changes¹,⁷
Understanding this timeline is critical for prevention.
Lipids, Inflammation, and Metabolic Risk: What to Test and Why
Standard Lipid Panel
What it measures: LDL-C, HDL-C, triglycerides
Why it matters: Foundational risk assessment, but incomplete alone
How to ask: “Can we review my lipid panel in the context of perimenopause/menopause and family history?”⁷
ApoB (Apolipoprotein B)
What it measures: Number of atherogenic lipoprotein particles
Why it matters: Predicts cardiovascular risk more accurately than LDL-C alone, especially in women with normal LDL⁸
How to ask: “Can we add ApoB to better assess particle-based risk?”⁸
Lipoprotein(a) [Lp(a)]
What it measures: Genetically inherited cholesterol particle
Why it matters: Identifies inherited risk not seen on standard panels; recommended at least once in adulthood⁹
How to ask: “Should I have a one-time Lp(a) test to assess inherited risk?”⁹
hs-CRP
What it measures: Chronic low-grade inflammation
Why it matters: Independently predicts cardiovascular events in women, even with normal cholesterol¹⁰
How to ask: “Can we check hs-CRP to evaluate inflammation-related risk?”¹⁰
HbA1c ± Fasting Insulin
What it measures: Glucose regulation and insulin resistance
Why it matters: Metabolic dysfunction is a major driver of heart disease and dementia in women⁴,⁵
How to ask: “Can we track my glucose and insulin trends over time?”⁴
Brain Health and Dementia: Why Midlife Is the Window for Prevention
Emerging research led by Dr. Lisa Mosconi shows that brain changes associated with Alzheimer’s disease begin decades before symptoms, often during perimenopause.⁵,¹¹
Neuroimaging and metabolic studies demonstrate that:
-
Midlife hormonal transitions affect brain energy metabolism
-
Women experience sex-specific brain changes during menopause
-
These changes influence long-term dementia risk⁵,¹¹
As a result, early testing and trend monitoring are essential.
Brain-Relevant Tests to Discuss
-
HbA1c and fasting insulin⁵
-
Lipid panel and ApoB⁷
-
Vitamin B12 and folate¹²
-
Homocysteine (vascular and cognitive risk marker)¹³
How to ask:
“I want to support long-term brain health. Are there metabolic or vascular markers we should monitor over time?”
Bone Health and Body Composition: Why Waiting Until 65 Is Too Late
Traditional DEXA screening begins at age 65. However, estrogen, progesterone, and testosterone decline much earlier — accelerating bone loss, muscle loss, and metabolic risk.¹⁴
Longevity and orthopedic experts, including Dr. Vonda Wright, recommend baseline DEXA scans in the 30s–40s to guide early lifestyle and resistance-training interventions.¹⁵
DEXA Testing
-
Bone density DEXA: Identifies early bone loss
-
Whole-body DEXA: Assesses lean mass and fat distribution
How to ask:
“Would a baseline DEXA scan help me track bone and muscle health over time?”¹⁴,¹⁵
The Missing Tool: Symptom Tracking Over Time
Because labs are snapshots, symptom tracking provides the context clinicians need. Research supports longitudinal symptom documentation to improve diagnosis and care during perimenopause.¹–³
Tracking includes:
-
Cycle changes
-
Sleep quality
-
Mood and anxiety
-
Brain fog
-
Energy levels
-
Joint pain
-
Vasomotor symptoms
Find a Certified Menopause Practitioner
Navigating perimenopause and menopause is complex, and many women benefit from working with healthcare professionals who have specialized training in menopause care.
The Menopause Society offers a public directory of clinicians certified in menopause medicine and trained in evidence-based midlife care.
These practitioners can help women interpret symptoms, labs, and testing trends and develop individualized care plans.
Take This to Your Healthcare Provider:
Tests by Body System
Cardiometabolic
-
Lipid panel
-
ApoB
-
Lipoprotein(a)
-
hs-CRP
-
HbA1c ± fasting insulin
Hormonal
-
Estradiol
-
Progesterone
-
FSH / LH
-
Testosterone (total & free)
-
SHBG
Brain & Cognitive
-
Vitamin B12
-
Folate
-
Homocysteine
-
Metabolic markers
Bone & Body Composition
-
DEXA (bone density)
-
Whole-body DEXA (optional)
Thrive for Longevity Disclosure
Thrive for Longevity provides evidence-based educational content and does not offer medical advice. Women are encouraged to work with qualified, menopause-educated healthcare professionals to determine appropriate testing and care based on their unique history.
References
-
Appelman Y, Gulati M, van Rijn BB, et al. Cardiovascular disease in women: traditional and sex-specific risk factors. European Heart Journal. 2025;ehaf1001.
-
Davis SR, Lambrinoudaki I, Lumsden M, et al. Menopause. Lancet. 2015;386(9996):1303-1312.
-
Faubion SS, Larkin LC, Stuenkel CA, et al. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
-
Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019;140:e596-e646.
-
Mosconi L. The XX Brain. Viking; 2020.
-
Colditz GA, Bohlke K, Berkey CS. Breast cancer risk accumulation starts early. CA Cancer J Clin. 2014;64(5):356-367.
-
American Heart Association. Heart disease and stroke statistics—2024 update. Circulation. 2024;149:e347-e913.
-
Sniderman AD, Thanassoulis G, Williams K, et al. Apolipoprotein B and cardiovascular risk. European Heart Journal. 2024;45:2419-2429.
-
Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) consensus statement. European Heart Journal. 2022;43:3925-3946.
-
Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and cardiovascular risk in women. N Engl J Med. 2000;342:836-843.
-
Mosconi L, Rahman A, Diaz I, et al. Sex differences in Alzheimer risk. Neurology. 2021;97:e827-e839.
-
O’Leary F, Samman S. Vitamin B12 in health and disease. Br J Nutr. 2010;104:315-329.
-
Smith AD, Refsum H. Homocysteine and cognition. Lancet. 2016;388:1737-1738.
-
U.S. Preventive Services Task Force. Osteoporosis screening. JAMA. 2025;333:721-727.
-
Wright V. Unbreakable. Rodale; 2022.
